Dihydroartemisinin- piperaquine dispersible

Dihydroartemisinin- piperaquine dispersible

Product development
-
Patient confirmatory
DHA-PQP dispersible
Alfasigma
Asexual blood stages
Paediatric formulation
No progress report in last two years
3-day cure, artemisinin-based combination therapies (TPP-1)
Product vision
  • 3-day cure, artemisinin-based combination therapy 
Dosing

  • Once-daily for 3 days
Efficacy

  • Efficacy in adults established

  • Pharmacokinetic bridging strategy to establish paediatric dose
Key features

  • Anticipated comparatively long post-treatment protection
Challenges
  • Potential cardiac monitoring restrictions
  • Confirmed piperaquine resistance in Greater Mekong Sub-region 
Status
  • Pharmacokinetic studies in children completed
  • Dossier under development for submission to European Medicines Agency (EMA)
Next milestone

  • Submission to EMA
Project Director

  • Adam Aspinall